His primary scientific interests are in Immunology, Transforming growth factor beta, Transforming growth factor, Cytokine and Cancer research. His Immunology study integrates concerns from other disciplines, such as Cytotoxic T cell and Interleukin 12. His Transforming growth factor beta research integrates issues from IL-2 receptor, Molecular biology, Knockout mouse and Antibody, Anti-SSA/Ro autoantibodies.
Transforming growth factor is a subfield of Cell biology that John J. Letterio explores. His Cytokine study also includes fields such as
His main research concerns Immunology, Cancer research, Cell biology, Transforming growth factor and Transforming growth factor beta. His Cancer research research is multidisciplinary, incorporating perspectives in Cell culture, Carcinogenesis, Cancer, Cell growth and Bone marrow. His study in Cell biology is interdisciplinary in nature, drawing from both R-SMAD, Cellular differentiation and Gene isoform.
His work in Transforming growth factor addresses subjects such as Receptor, which are connected to disciplines such as Genetically modified mouse and Cell. His Transforming growth factor beta research also works with subjects such as
John J. Letterio mostly deals with Cancer research, T cell, Immunology, Bone marrow and Breast milk. John J. Letterio interconnects Chemotherapy, Antibody-dependent cell-mediated cytotoxicity, Multiple myeloma, Bortezomib and Transforming growth factor beta in the investigation of issues within Cancer research. His Transforming growth factor beta study combines topics from a wide range of disciplines, such as Ixazomib, Carfilzomib and Proteasome.
The various areas that John J. Letterio examines in his T cell study include Tumor necrosis factor alpha, Colitis and Effector. In the subject of general Immunology, his work in Immune system and Experimental autoimmune encephalomyelitis is often linked to Cyclin-dependent kinase 5, thereby combining diverse domains of study. The study incorporates disciplines such as Postpartum period, Internal medicine and Endocrinology in addition to Breast milk.
His primary areas of study are Cancer research, T cell, Tumor necrosis factor alpha, Antibody and Combination therapy. His Cancer research study combines topics in areas such as Haematopoiesis, Bone marrow failure, Stem cell and Aplastic anemia, Bone marrow. Research on Immunology and Immune system is a part of his T cell study.
The Tumor necrosis factor alpha study combines topics in areas such as Encephalomyelitis and Signal transduction. His research integrates issues of Receptor, Chemotherapy and Cell growth in his study of Antibody. Many of his studies involve connections with topics such as Cell and Combination therapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
REGULATION OF IMMUNE RESPONSES BY TGF-β*
John James Letterio;Anita B. Roberts.
Annual Review of Immunology (1998)
TGF-β1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
Julien C. Marie;John James Letterio;Marc Gavin;Alexander Y. Rudensky.
Journal of Experimental Medicine (2005)
Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response.
Gillian S. Ashcroft;Xiao Yang;Adam B. Glick;Michael Weinstein.
Nature Cell Biology (1999)
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β
Xiao Yang;John J. Letterio;Robert J. Lechleider;Lin Chen.
The EMBO Journal (1999)
CD4+CD25+ Regulatory T Cells Can Mediate Suppressor Function in the Absence of Transforming Growth Factor β1 Production and Responsiveness
Ciriaco A. Piccirillo;John J. Letterio;Angela M. Thornton;Rebecca S. McHugh.
Journal of Experimental Medicine (2002)
Transforming Growth Factor-β Production and Myeloid Cells Are an Effector Mechanism through Which CD1d-restricted T Cells Block Cytotoxic T Lymphocyte–mediated Tumor Immunosurveillance Abrogation Prevents Tumor Recurrence
Masaki Terabe;So Matsui;Jong-Myun Park;Mizuko Mamura.
Journal of Experimental Medicine (2003)
A Role for Endogenous Transforming Growth Factor β1 in Langerhans Cell Biology: The Skin of Transforming Growth Factor β1 Null Mice Is Devoid of Epidermal Langerhans Cells
Teresa A. Borkowski;John J. Letterio;Andrew G. Farr;Mark C. Udey.
Journal of Experimental Medicine (1996)
Maternal rescue of transforming growth factor-beta 1 null mice.
John J. Letterio;Andrew G. Geiser;Ashok B. Kulkarni;Nanette S. Roche.
Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Yu An Yang;Oksana Dukhanina;Binwu Tang;Mizuko Mamura.
Journal of Clinical Investigation (2002)
Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance
Stephanie Dillon;Sudhanshu Agrawal;Kaustuv Banerjee;John Letterio.
Journal of Clinical Investigation (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: